TRUE Private Wealth Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
– Sell
-5,853
Closed -$768K – 243
2022
Q4
$768K Buy
5,853
+1,649
+39% +$213K 0.12% 87
2022
Q3
$491K Buy
+4,204
New +$522K 0.07% 109
2021
Q1
– Sell
-162
Closed -$24K – 449
2020
Q4
$24K Buy
162
+12
+8% +$1.72K ﹤0.01% 428
2020
Q3
$20K Hold
150
– – ﹤0.01% 413
2020
Q2
$20K Sell
150
-52
-26% -$6.63K ﹤0.01% 411
2020
Q1
$21K Sell
202
-4
-2% -$461 ﹤0.01% 379
2019
Q4
$24K Buy
+206
New +$23K ﹤0.01% 463
2019
Q3
– Sell
-56
Closed -$6K – 455
2019
Q2
$6K Buy
+56
New +$5.96K ﹤0.01% 607
2018
Q4
– Sell
-3,640
Closed -$444K – 557
2018
Q3
$444K Buy
3,640
+483
+15% +$56.9K 0.06% 177
2018
Q2
$347K Sell
3,157
-290
-8% -$31K 0.05% 196
2018
Q1
$367K Buy
3,447
+306
+10% +$33.9K 0.06% 163
2017
Q4
$335K Buy
+3,141
New +$336K 0.06% 172

Other funds holding IBB

TRUE Private Wealth Advisors's IBB Position: Q1 2023 in Review

TRUE Private Wealth Advisors sold out of iShares Biotechnology ETF (IBB) in Q1 2023, closing a stake of 5,853 shares — an estimated $768K sold.

TRUE Private Wealth Advisors first reported a position in IBB in Q4 2017 and held it in 12 quarters. The position peaked at $768K in Q4 2022. 866 funds tracked by Wall St. Rank hold IBB as of Q1 2023.

  • TRUE Private Wealth Advisors reported no remaining iShares Biotechnology ETF position as of Q1 2023 after selling out during the quarter.
  • TRUE Private Wealth Advisors sold 5,853 iShares Biotechnology ETF shares in Q1 2023, an estimated $768K.
  • TRUE Private Wealth Advisors first reported a position in iShares Biotechnology ETF in Q4 2017 and held it in 12 quarters.
  • TRUE Private Wealth Advisors's iShares Biotechnology ETF position peaked at $768K in Q4 2022.
  • 866 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2023.

Based on TRUE Private Wealth Advisors's 13F filing for Q1 2023, filed 11 May 2023.